Herbal formula
Kan Jang (Andrographis and Eleuthero)
Also known as Kan Jang tablets, Kan Jang First Defence, Nergecov, agaDA, SHA-10 and SHE-3 extracts, andrographis with Siberian ginseng
An andrographis and eleuthero blend that eased cold symptoms in manufacturer-linked trials; its andrographis can cause anaphylaxis.
Main use: Common cold symptoms
Promising clinical evidence
2 ingredients
Updated October 10, 2026
Key points
-
01
A fixed andrographis and eleuthero combination
Kan Jang pairs a standardized andrographis herb extract with a small amount of eleuthero root extract. Its trial results apply to this product, not to either herb alone.
-
02
Modest relief of cold symptoms
Placebo-controlled trials found faster relief of sore throat and other cold symptoms, and a 2021 trial cut sick leave from 3.02 to 2.38 days.
-
03
Research is mostly manufacturer-linked
The main trials were sponsored by or co-authored with the Swedish manufacturer and were small. Independent replication is lacking.
-
04
Andrographis can cause anaphylaxis
Australia logged 287 anaphylaxis reports, including a death, and barred andrographis from new low-risk listed medicines from 17 September 2026.
-
05
Check the label: not every Kan Jang has andrographis
In Sweden, the medicine sold simply as Kan Jang is an echinacea, Malabar nut, and eleuthero solution. The andrographis capsules are Kan Jang First Defence.
Kan Jang is a fixed combination of two herbal extracts taken at the first signs of a cold: a standardized extract of andrographis (Andrographis paniculata) herb, coded SHA-10, and a much smaller amount of eleuthero (Eleutherococcus senticosus) root extract, coded SHE-3. It is made by the Swedish Herbal Institute (SHI Pharma) in Vallberga, Sweden, and it is the andrographis product with the longest run of clinical trials behind it. In Denmark it is a registered herbal medicine in tablet form for the relief of cold symptoms and for tiredness during convalescence, according to the Danish medicines reference Medicin.dk. The name needs care, though. In Sweden, the medicine now sold simply as Kan Jang is an oral solution of echinacea, Malabar nut (Justicia adhatoda), and eleuthero that contains no andrographis, while the andrographis and eleuthero capsules are sold there as Kan Jang First Defence. This page is about the andrographis and eleuthero combination, the product tested in the trials described below.
Andrographis is a bitter herb of South Asian traditional medicine, and eleuthero, sold for decades as Siberian ginseng, is the root of a shrub from the Russian Far East and northern China, but Kan Jang itself is Swedish. SHI says it developed the combination and first put Kan Jang on the Swedish market in 1978, and the authors of a 2021 trial write that the andrographis and eleuthero combination has been used in Scandinavia for more than 30 years to relieve symptoms of colds and influenza. Placebo-controlled trials of the combination were published from 2000 onward, with later studies run in Armenia and Georgia. The brand later split in two. Sweden’s Medical Products Agency authorized the Kan Jang oral solution as a natural remedy in 2006 and re-registered it as a traditional herbal medicinal product in 2010, a status based on long use rather than proof of effect; that solution is the andrographis-free formula. During the COVID-19 pandemic the andrographis combination was also tested in people with mild COVID-19 under the name Nergecov.
How Kan Jang might work is not settled. Andrographis is the main active partner: products are standardized to its bitter diterpene lactones, chiefly andrographolide, and in laboratory and animal studies summarized by the European Medicines Agency (EMA), andrographis extracts altered immune responses, lowered blood pressure, and lowered blood sugar in diabetic rats. Eleuthero is mostly used as an adaptogen, a substance said to raise endurance and resistance to stress, according to the US LactMed database, but each Kan Jang dose contains only a little of it. The authors of the 2021 trial, who include the president of the manufacturer’s research company, describe the combination as antiviral, immunomodulatory, and anti-inflammatory, and in their trial white blood cell counts and the erythrocyte sedimentation rate, a blood marker of inflammation, normalized faster than with placebo. None of this shows which ingredient does what in people. This page covers what is in the products, what the combination’s own trials found, how it is taken, and the serious allergy risk it carries from andrographis. Nothing here is medical advice.
See also
Herbs for Colds, Flu and Immunity02 The blend
What’s in it
Ingredients in label order. Results from trials of this formula belong to the combination, not to any single herb in it.
-
Andrographis · Herb (aerial parts), extract SHA-10
33–55 mg extract per tablet, equal to 5 mg andrographolides (Danish tablet)
Andrographis paniculata
The main active partner, standardized to andrographolides, its best-studied bitter compounds. Extract weight varies by product: EMA describes 85 mg per unit and the 2021 trial capsule held 195 mg. Trial doses gave 60 mg of andrographolides a day.
Read the andrographis monograph →
-
Eleuthero · Root, extract SHE-3
5.7 mg extract per tablet, equal to about 120 mg dried root (Danish tablet)
Eleutherococcus senticosus
A small amount of the “Siberian ginseng” root, mostly used as an adaptogen. EMA describes 10 mg of extract, equal to 120 mg of crude root, per unit. The trials tested the combination, so they cannot show what eleuthero adds.
Read the eleuthero (siberian ginseng) monograph →
03 Evidence
What the research shows
Our rating for common cold symptoms, based on trials of this combination.
The first published trials were small but placebo-controlled. Melchior and colleagues (Phytomedicine 2000) reported two randomized, double-blind trials in uncomplicated upper respiratory tract infections: a pilot study completed by 46 patients and a phase III trial completed by 179, in which Kan Jang was taken three times a day for exactly three days. In the phase III trial both the patients’ total symptom score and the doctors’ diagnosis score improved significantly more than with placebo, and in both studies throat symptoms improved most. Gabrielian and colleagues (Phytomedicine 2002) then gave Kan Jang or placebo for five days to people with acute upper respiratory infections, including sinusitis; 95 people on Kan Jang and 90 on placebo completed the study. Total scores improved significantly, overall and in the sinusitis subgroups, with the clearest effects on headache, nasal and throat symptoms, and general malaise, while cough and eye symptoms did not differ and temperature fell only moderately. Both papers list Georg Wikman as an author; in 2021 he declared a conflict of interest as president of SHI’s research and development company.
The most rigorous trial is the most recent. Narimanyan and colleagues (Journal of Traditional and Complementary Medicine 2021) enrolled adults aged 18 to 65 in Armenia whose cold symptoms had started no more than 36 hours earlier; 179 completed the study, 94 on Kan Jang and 85 on placebo. Six capsules a day for five days supplied 60 mg of andrographolides. In this quadruple-blind phase II trial, sick leave averaged 2.38 days with Kan Jang and 3.02 days with placebo, a reduction of a little over 21%, and all the measured symptoms, including sore throat, runny nose, nasal congestion, hoarseness, cough, headache, and fatigue, eased more than with placebo from the second day. Mild itching affected four people on Kan Jang and six on placebo, and no allergic reactions were seen. The Swedish Herbal Institute sponsored the trial and made, packed, and blinded the capsules; one author was president of its research company, one a contractor to it, and one its former head of research. The authors list the relatively small sample as a limitation.
Evidence in children rests on one trial. Spasov and colleagues (Phytotherapy Research 2004) studied 130 children aged 4 to 11 with uncomplicated colds over 10 days, comparing standard treatment alone, standard treatment plus Kan Jang tablets, and standard treatment plus Immunal, an echinacea preparation. Kan Jang was reported to work better than the echinacea product when started early, with less nasal secretion and congestion, faster recovery, and less use of standard medicines, and no side effects were reported. There was no placebo group, the published group sizes (53, 41, and 39) add up to 133 rather than 130, and Wikman was again a co-author. In adults with mild COVID-19 in Georgia, Ratiani and colleagues (Pharmaceuticals 2022) published an interim analysis of 86 patients in a placebo-controlled trial of higher-dose Kan Jang capsules, sold as Nergecov, taken for 14 days alongside paracetamol (acetaminophen). They reported less progression to severe disease and lower levels of the inflammatory messenger interleukin-6. It was an unfinished trial with SHI’s former head of research among its authors, and it does not establish Kan Jang as a COVID-19 treatment.
Systematic reviews put these trials in context. Poolsup and colleagues (Journal of Clinical Pharmacy and Therapeutics 2004) pooled three randomized trials with 433 patients and found that the andrographis and eleuthero combination improved symptom severity scores by 2.13 points more than placebo (95% confidence interval 1.00 to 3.26); andrographis alone also beat placebo. Hu and colleagues (PLoS One 2017), funded by the UK National Institute for Health Research, reviewed 33 randomized trials with 7,175 patients of andrographis products, including Kan Jang tablets alongside Chinese and Indian preparations. Andrographis improved cough and sore throat compared with placebo and shortened symptoms and sick leave compared with usual care, but the trials were of poor overall quality and most products came without manufacturing or quality-control details. What is missing for Kan Jang is independent replication: its trials were run with the manufacturer, enrolled a few hundred people at most, and were far too small to detect rare but serious reactions such as anaphylaxis. None of the trials described here compared Kan Jang with andrographis alone, so the eleuthero’s contribution is unknown, and results from single-herb andrographis extracts, which differ in solvent and dose, cannot be credited to Kan Jang.
Regulators have not endorsed the combination on the strength of these trials. When the EMA assessed andrographis leaf in 2014, it noted that most studies had used a fixed-combination product and left them out, because its task was a single-herb monograph; it then judged the single-herb trials too weak for “well-established use,” found no single-herb product with 15 years of medicinal use in the European Union, and issued no monograph. Its survey of member states found only one combination product containing andrographis in Denmark and no andrographis medicine, single or combined, with a standard German marketing authorization. Denmark today lists Kan Jang tablets as a registered herbal medicine (naturlægemiddel). In the United States, herbal products like these are generally sold as dietary supplements, which, as LactMed notes, do not need extensive premarketing approval from the Food and Drug Administration (FDA), and the National Center for Complementary and Integrative Health (NCCIH) lists andrographis among cold remedies with insufficient evidence. Australia went furthest: from 17 September 2026 its Therapeutic Goods Administration (TGA) no longer allows andrographis in new low-risk listed medicines, a decision about safety rather than effectiveness.
04 In practice
How it is taken
Products differ, so check exactly what is in the pack. The Danish registered Kan Jang tablet contains 33–55 mg of andrographis herb extract, equivalent to 5 mg of total andrographolides, plus 5.7 mg of eleuthero root extract, equivalent to about 120 mg of dried root (Medicin.dk). The EMA’s assessment report describes the product used in the early trials as 85 mg of andrographis extract, equivalent to 5 mg of andrographolides, with 10 mg of eleuthero extract equivalent to 120 mg of crude root, while each capsule in the 2021 trial held 195 mg of SHA-10, standardized to 10 mg of diterpene lactones, and 11.4 mg of eleuthero extract. Extract weights vary because each batch is standardized to its active content. In Sweden and Denmark the combination is also sold as Kan Jang First Defence capsules, which contain the SHA-10 and SHE-3 extracts and carry immune-support wording. The Swedish Kan Jang oral solution is a different medicine, with echinacea, Malabar nut, and eleuthero but no andrographis, taken as 15 ml twice a day by adults and adolescents from age 12.
For the Danish tablets, the adult dose is four tablets three times a day, 12 tablets supplying 60 mg of andrographolides, the same daily amount as in the main adult trials, and the tablets should not be taken for more than two to three months. The adult trials themselves lasted only three to five days and started at the first symptoms; in the 2021 trial people had to begin within 36 hours. Kan Jang First Defence is marketed at two capsules morning and evening, with one capsule morning and evening as a maintenance dose for longer use, a pattern the trials did not test. For the Swedish oral solution, the label limits a course to 10 days and advises contacting a doctor if symptoms persist after 10 days, get worse, or come with a high fever, which is sensible advice for any cold remedy. Whatever the product, stop at the first sign of an allergic reaction, such as itching, hives, or swelling, and get emergency help for any breathing difficulty or throat swelling.
Choosing a product: read the ingredient list rather than the brand name, because “Kan Jang” covers formulas with and without andrographis, and many other cold and “immune” products combine andrographis with echinacea or other herbs. A product that names Andrographis paniculata and states its andrographolide content per dose lets you compare it with the 60 mg a day used in the trials. Avoid taking two andrographis-containing products at the same time. In Australia, some existing andrographis products are being recalled after the TGA’s 2026 decision, and the TGA advises consumers to reconsider whether they need andrographis at all, given its unpredictable and potentially fatal allergy risk. Do not use any andrographis product after a previous reaction to one. Talk to a pharmacist first if you take regular medicines, have high blood pressure or a long-term illness, are pregnant or breastfeeding, or are choosing a remedy for a child or teenager.
05 Caution
Before you use Kan Jang (Andrographis and Eleuthero)
In the trials, Kan Jang was reported to be well tolerated: in the 2021 trial the only common complaint was mild itching, in four people on Kan Jang and six on placebo, and no side effects were reported in the children’s trial. Medicin.dk lists rare allergic skin reactions (0.01–0.1%), insomnia of unknown frequency, and, very rarely, heart rhythm disturbances or a rise in blood pressure in people with high blood pressure. Andrographis is intensely bitter, and among 1,368 Australian adverse event reports for andrographis medicines up to the end of 2025, loss of taste and altered taste were among the most common terms. The serious risk is anaphylaxis, a sudden and potentially fatal allergic reaction. By the end of 2025 the TGA had received 287 reports of anaphylaxis linked to andrographis-containing medicines, including a death reported in 2024. Most reactions began within 30 minutes, occurred on first use or after earlier trouble-free use, and were treated with adrenaline (epinephrine) or in hospital, and more than half of the people affected had no history of allergy. Trials of a few hundred people cannot measure a risk of this kind.
Do not take Kan Jang if you have ever reacted to an andrographis product, and the TGA advises that people who have had a severe allergic reaction, including anaphylaxis, to any trigger should avoid andrographis medicines. Medicin.dk says the tablets should not be used in pregnancy or while breastfeeding because data are insufficient, and the EMA notes that the safety of andrographis in pregnancy and breastfeeding has not been studied. For children under 12 there is no established experience: the children’s trial was far too small to judge safety, and the Swedish oral solution is likewise not recommended under 12. The TGA counted 11 anaphylaxis cases in adolescents aged 12 to 17 and called them a particularly vulnerable group, since they may take adult doses without a caregiver nearby. Medicin.dk lists high blood pressure as a reason for caution and notes a lack of experience in people with reduced kidney function (an estimated filtration rate below 60 ml/min) or reduced liver function. People with autoimmune disease or a transplant, and anyone with a long-term illness, should speak with their doctor first.
None of the sources reviewed here reports a human interaction study of Kan Jang, so the cautions come from its ingredients. Blood thinners: andrographis inhibits platelet clumping in laboratory studies, and Memorial Sloan Kettering Cancer Center (MSKCC) advises caution with anticoagulant and antiplatelet drugs; in rats, Kan Jang at about 17 times the human dose did not significantly change warfarin levels or effect (EMA), and LactMed notes that eleuthero may increase bleeding. Blood pressure medicines: andrographis may add to their effect and caused brief falls in blood pressure in healthy people (MSKCC), yet Medicin.dk notes rare rises in people with high blood pressure, so watch readings either way. Diabetes medicines: andrographis lowered blood sugar in diabetic rats (EMA), while LactMed says eleuthero may raise it, so check glucose more often. Immunosuppressants: andrographis altered immune responses in animals, which could in theory work against these drugs. MSKCC also lists laboratory inhibition of CYP1A2, CYP2C9, CYP3A4, and UGT2B7, enzymes that clear many drugs, and possible interactions with aminophylline and chemotherapy, and eleuthero has been linked to raised or falsely high digoxin blood tests.
Get emergency help at once for signs of anaphylaxis after a dose: difficulty breathing, swelling of the tongue or throat, wheezing, dizziness, collapse, or stomach pain and vomiting, which the TGA lists as warning signs. Anaphylaxis needs immediate adrenaline. The TGA notes that milder reactions can be mistaken for symptoms of the infection being treated, that a label warning does little for people without quick access to emergency care, and that ibuprofen and similar painkillers, alcohol, exercise, and the viral infection itself can make allergic reactions more likely or more severe, so avoid starting andrographis when you are alone or far from help. Kan Jang is meant only for uncomplicated colds. See a doctor rather than self-treating for a high fever, shortness of breath, chest pain, a severe sore throat with difficulty swallowing, earache, or facial pain that lingers, if symptoms worsen or have not improved within about 10 days, or if the person who is ill is a baby, an older adult, or someone with a weakened immune system or chronic heart or lung disease. Kan Jang does not replace vaccination or antiviral treatment for influenza or COVID-19.
06 Questions
Frequently Asked Questions
No. Kan Jang combines a standardized extract of andrographis with a small amount of eleuthero root extract, and its trial results belong to that combination. Single-herb andrographis products use different extracts and doses, so their results cannot be credited to Kan Jang, or the other way round. The allergy risk, however, comes with the andrographis in any of them.
It may help a little if taken early. Placebo-controlled trials found faster relief of sore throat and other symptoms, and in a 2021 trial of 179 adults who started within 36 hours of their first symptoms, sick leave averaged 2.38 days versus 3.02 on placebo. A 2004 review of three trials with 433 patients found a modest benefit. But the trials were small and run with the manufacturer, and independent confirmation is lacking.
Because the brand name now covers two formulas. In Sweden, the registered traditional medicine called simply Kan Jang is an oral solution of echinacea, Malabar nut, and eleuthero, approved on the basis of long use and not recommended under 12. The andrographis and eleuthero combination studied in trials is sold there as Kan Jang First Defence capsules, and in Denmark as Kan Jang tablets. Always check the ingredient list.
That has not been shown. The trials described here tested short courses of three to five days started at the first symptoms, not daily use to prevent colds, and they measured symptoms and sick leave rather than immune function. Kan Jang First Defence is marketed with a maintenance dose for longer use, but longer use also means longer exposure to the risk of anaphylaxis, which can appear after earlier trouble-free use.
Because of anaphylaxis. The TGA received 287 reports of anaphylaxis linked to andrographis medicines between 2005 and the end of 2025, including a death reported in 2024. Label warnings required since 2020 did not stop the reports, and the TGA concluded that the risk could not be managed in low-risk, self-selected medicines. From 17 September 2026, new listed medicines can no longer contain andrographis.
It is not recommended under 12. Medicin.dk notes a lack of experience with the tablets in this age group, and the Swedish oral solution is also not recommended under 12. One 2004 trial gave Kan Jang tablets to 130 children aged 4 to 11 alongside standard treatment, but it had no placebo group and was far too small to show safety. Ask a doctor or pharmacist about a child’s cold, and seek care quickly for breathing difficulty or a high fever.
It should not be used. Medicin.dk advises against the tablets in pregnancy and breastfeeding because data are insufficient, and the EMA notes that the safety of andrographis in pregnancy and breastfeeding has not been studied. Pregnancy is also a poor time to risk a severe allergic reaction. Ask a midwife, doctor, or pharmacist which cold remedies are suitable.
Direct comparisons are rare; the only head-to-head trial described here, in children, found it worked better than an echinacea product. Other herbal products studied for respiratory infections include Sinupret for sinusitis, thyme and ivy for cough, pelargonium, and echinacea, each with its own evidence and cautions. Kan Jang stands out for the anaphylaxis risk of its andrographis. Rest, fluids, and time remain the basics.
07 References
Sources
These references support the claims on this page. They are not an endorsement of any product. Each ingredient’s monograph carries its own full source list.
-
Early intervention with Kan Jang® to treat upper-respiratory tract infections: A randomized, quadruple-blind study
Journal of Traditional and Complementary Medicine (PubMed 34765519), 2021
Narimanyan et al.: 179 adults aged 18–65 in Armenia, 94 on Kan Jang and 85 on placebo; six capsules a day (60 mg andrographolides) for five days; sick leave 2.38 versus 3.02 days; capsule composition; mild itching 4 versus 6; sponsored by the Swedish Herbal Institute; author conflicts.
-
Double-blind, placebo-controlled pilot and phase III study of activity of standardized Andrographis paniculata Herba Nees extract fixed combination (Kan jang) in the treatment of uncomplicated upper-respiratory tract infection
Phytomedicine (PubMed 11081985), 2000
Melchior et al.: pilot (46 patients) and phase III (179 patients) double-blind trials; three days of Kan Jang in the phase III trial significantly improved total symptom and diagnosis scores versus placebo, most for throat symptoms.
-
A double blind, placebo-controlled study of Andrographis paniculata fixed combination Kan Jang in the treatment of acute upper respiratory tract infections including sinusitis
Phytomedicine (PubMed 12487322), 2002
Gabrielian et al.: 95 on Kan Jang and 90 on placebo for five days; total scores improved, including in sinusitis subgroups; headache, nasal and throat symptoms, and malaise improved most; cough and eye symptoms did not differ.
-
Comparative controlled study of Andrographis paniculata fixed combination, Kan Jang and an Echinacea preparation as adjuvant, in the treatment of uncomplicated respiratory disease in children
Phytotherapy Research (PubMed 14750201), 2004
Spasov et al.: 130 children aged 4–11, 10 days; Kan Jang tablets (53), Immunal echinacea (41), or standard treatment only (39); Kan Jang reduced nasal secretion and congestion and medication use; no placebo; no side effects reported.
-
Andrographis paniculata in the symptomatic treatment of uncomplicated upper respiratory tract infection: systematic review of randomized controlled trials
Journal of Clinical Pharmacy and Therapeutics (PubMed 14748896), 2004
Poolsup et al.: three trials, 433 patients; andrographis with eleuthero improved symptom severity scores by 2.13 points (95% CI 1.00–3.26) over placebo; andrographis alone also more effective than placebo.
-
Andrographis paniculata (Chuān Xīn Lián) for symptomatic relief of acute respiratory tract infections in adults and children: A systematic review and meta-analysis
PLoS One (PubMed 28783743), 2017
Hu et al., funded by the UK National Institute for Health Research: 33 trials, 7,175 patients, including Kan Jang tablets; improved cough and sore throat versus placebo; poor overall trial quality; manufacturing details seldom reported.
-
Efficacy of Kan Jang® in patients with mild COVID-19: interim analysis of a randomized, quadruple-blind, placebo-controlled trial
Pharmaceuticals (PubMed 36015163), 2022
Ratiani et al.: interim analysis of 86 patients with mild COVID-19 given Kan Jang/Nergecov (90 mg andrographolides a day) or placebo for 14 days; reported less progression and lower IL-6; trial still in progress.
-
Assessment report on Andrographis paniculata Nees, folium
European Medicines Agency (EMA/HMPC/320433/2012), 2014
Kan Jang composition (85 mg andrographis extract, 5 mg andrographolides, 10 mg eleuthero extract); combination trials excluded; no monograph; member-state product survey; warfarin rat study; immune, blood pressure, and blood sugar effects in animals; pregnancy not studied.
-
Kan Jang® (Naturlægemiddel)
Medicin.dk (Dansk Lægemiddel Information), 2025
Danish registered tablet: 33–55 mg andrographis extract (5 mg andrographolides) and 5.7 mg eleuthero extract per tablet; four tablets three times daily, no more than 2–3 months; no experience under 12; avoid in pregnancy and breastfeeding; side effects; caution in hypertension.
-
Public Assessment Report: Kan Jang, oral solution
Medical Products Agency (Läkemedelsverket), Sweden, 2010
Swedish Kan Jang oral solution contains Justicia adhatoda, echinacea root, and eleuthero root extracts; authorized as a natural remedy in 2006 and registered as a traditional herbal medicinal product in 2010; not recommended under 12 or in pregnancy.
-
Kan Jang®
SHI Pharma (Swedish Herbal Institute), 2024
Manufacturer page for the current Swedish oral solution: echinacea, Malabar nut, and eleuthero per ml; 15 ml twice daily from age 12, for up to 10 days; developed by SHI and on the Swedish market since 1978.
-
Andrographis paniculata (Andrographis) and anaphylaxis - updated safety review and supplementary report
Therapeutic Goods Administration (Australia), 2026
287 anaphylaxis reports to December 2025, including a death reported in 2024; onset mostly within 30 minutes, on first use or after previous use; most without allergy history; 11 adolescent cases; NSAIDs, alcohol, exercise, and infection as cofactors.
-
High-moderate risk changes to permissible ingredients - Andrographis paniculata 2026
Therapeutic Goods Administration (Australia), 2026
Andrographis removed from the Permissible Ingredients Determination from 17 September 2026; label warning required since 2020; fatal case reported June 2024; consumers advised to reconsider use.
-
Andrographis
Memorial Sloan Kettering Cancer Center, About Herbs, 2021
Herb-drug interactions: CYP1A2, 2C9, and 3A4 and UGT2B7 inhibition in the laboratory; caution with anticoagulants, antiplatelets, blood pressure drugs, chemotherapy, and aminophylline; transient blood pressure falls in healthy subjects.
-
Eleuthero
Drugs and Lactation Database (LactMed), National Institute of Child Health and Human Development (PubMed 30000865), 2006
Eleuthero mostly used as an adaptogen; may increase blood pressure, bleeding, and blood sugar; no lactation data; dietary supplements do not need extensive FDA premarketing approval.
-
Colds, Flu, and Complementary Health Approaches: Usefulness and Safety
National Center for Complementary and Integrative Health (NIH), 2016
Lists andrographis among approaches with insufficient evidence to show whether they prevent colds or relieve cold symptoms.